Category: Ocrevus

Phase 4 Trial Will Test if Ocrevus Can Prevent MS Onset in RIS Patients

Yale University is launching CELLO, a multicenter study to investigate the efficacy of Ocrevus (ocrelizumab) in treating people with lesions suggestive of multiple sclerosis (MS),…

Stuart Schlossman

COVID-19 in ocrelizumab-treated people with multiple sclerosis

  Abstract Background: There are limited data on the impact of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory…

Stuart Schlossman

Black MS Patients See More Rapid B-Cell Repopulation

  May have implications for timing of lab draws and anti-CD20 dosing, researchers say by Ed Susman, Contributing Writer, MedPage Today April 20, 2021…

Stuart Schlossman

New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis

April 16, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no…

Stuart Schlossman

FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis

Click HERE to Subscribe for the MS Beacon Newsletter ·        Approval based on data from the randomized, double-blind ENSEMBLE PLUS…

Stuart Schlossman

New Data Further Reinforce Genentech’s Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Sclerosis

* 75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease…

Stuart Schlossman

Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS

Jul 02, 2020 — Mark Freedman, MD, outlines a retrospective trial presented at the Consortium of Multiple Sclerosis Centers (CMSC)…

Stuart Schlossman

New 6-Year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in Relapsing Multiple Sclerosis

Post-hoc analysis from 6 years of Phase III open-label extension studies showed Ocrevus treatment reduced the risk of needing a…

Stuart Schlossman

Shorter Ocrelizumab Infusion Accepted for FDA Review

The FDA has accepted an sBLA for a version of Genentech’s ocrelizumab with a shorter administration time for the treatment…

Stuart Schlossman

Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS

Feb 17, 2020 – By Ed Tobia Ocrevus (ocrelizumab) bolted out of the starting gate after it was approved for use…

Stuart Schlossman

Categories

Latest Blog Posts